351. Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage
- Author
-
Persio Dello Sbarba, Silvia Bono, and Matteo Lulli
- Subjects
0301 basic medicine ,genetic structures ,medicine.drug_class ,Economic shortage ,lcsh:Computer applications to medicine. Medical informatics ,Original research ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Biochemistry, Genetics and Molecular Biology ,hemic and lymphatic diseases ,medicine ,lcsh:Science (General) ,Cell survival ,Multidisciplinary ,business.industry ,Myeloid leukemia ,Imatinib ,leukemia stem cells ,glucose shortage ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Cancer research ,lcsh:R858-859.7 ,Trypan blue ,Stem cell ,business ,medicine.drug ,lcsh:Q1-390 - Abstract
The data presented here are related to the original research article entitled "Imatinib enhances the maintenance of Chronic Myeloid Leukemia (CML) stem cell potential in the absence of glucose" (Bono et al., 2018). The sensitivity to the tyrosine kinase inhibitor imatinib-mesylate (IM) of KCL22 CML cells cultured under glucose shortage have been determined by scoring cell survival/growth via trypan blue exclusion and stem cell potential via Culture Repopulation Ability (CRA) assay. Discussion of the data can be found in Bono et al. (2018).
- Published
- 2018